JCJaw-Wen Chen

Jaw-Wen Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jaw-Wen Chen has a total of 340 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Glycemic control and renal function decline in patients with chronic coronary syndrome: A multicenter cohort study

    by An‐Yu Cheng, Chin‐Chou Huang, Hsin‐Bang Leu, Wei‐Hsian Yin, Wei‐Kung Tseng, Yen‐Wen Wu, Tsung‐Hsien Lin, Hung‐I Yeh, Kuan‐Cheng Chang, Ji‐Hung Wang, et al.

    Aims/Introduction: Diabetes mellitus significantly contributes to renal complications, especially in patients with coronary artery disease (CAD). Effective glycemic control is important; however, the ideal hemoglobin A1c (HbA1c) targets for this population remain uncertain. This observational cohort study aimed to identify appropriate HbA1c targets for patients with diabetes and chronic coronary syndrome. Materials and Methods: This study included 1,223 patients with chronic coronary syndrome, which were identified from a multicenter cohort registry study. Among them, there were 698 patients with diabetes. Patients were categorized based on their diabetes status and HbA1c levels. The primary outcome was the incidence of minor and major renal events, defined as a decline in the estimated glomerular filtration rate (eGFR) of more than 25% and 50%. Cox proportional hazards regression models were employed to assess the impact of glycemic control on renal function. Results: Over a mean follow‐up of 3.2 ± 2.0 years, the highest incidences of minor renal events were noted in the group with diabetes and HbA1c ≥ 7.5% (25.1%), followed by diabetes and HbA1c < 6.5% (21.2%). Compared to the group without diabetes, the adjusted hazard ratios (95% confidence intervals) for minor renal events in the groups with diabetes and HbA1c ≥ 7.5%, HbA1c 7.0–7.4%, HbA1c 6.5–6.9%, and HbA1c < 6.5% were 3.06 (2.08–4.50), 1.75 (1.08–2.84), 1.32 (0.81–2.23), and 2.59 (1.58–4.24), respectively. Conclusions: Achieving HbA1c of 6.5 to 6.9% is associated with a reduced risk of renal complications in patients with diabetes and chronic coronary syndrome.


  • Open Access

    Prognostic utility of neutrophil gelatinase-associated lipocalin (NGAL) levels for cardiovascular events in patients with stable coronary artery disease treated with percutaneous coronary intervention: a prospective longitudinal cohort study

    by Ting-Yu Lin, Hsin-Bang Leu, Yen-Wen Wu, Wei-Kung Tseng, Tsung-Hsien Lin, Hung-I Yeh, Kuan-Cheng Chang, Ji-Hung Wang, Wei-Hsian Yin, Chau-Chung Wu, et al.

    Introduction: Neutrophil gelatinase-associated lipocalin (NGAL) modulates the enzymatic activity of matrix metalloproteinase-9, which is an important mediator of plaque instability in atherosclerosis. High NGAL levels can independently predict all-cause mortality and major adverse cardiac events (MACE) in patients with acute myocardial infarction (AMI). However, studies that have measured NGAL levels in patients with stable coronary artery disease (CAD) are limited. Furthermore, no significant prognostic predictive value between NGAL levels and stable CAD has been established. Hypothesis: We aimed to investigate the prognostic role of NGAL levels in a prospective cohort study of patients with stable CAD treated with percutaneous coronary intervention (PCI). Methods: A total of 2,238 stable patients with CAD and a previous PCI were enrolled in a multicenter prospective observational study (The National Taiwan Biosignature Research, NTBR) in Taiwan. The primary outcome was the occurrence of MACE (cardiovascular death, nonfatal myocardial infarction, and ischemic stroke). The secondary outcome was a composite of cardiovascular events (cardiovascular death, nonfatal MI, nonfatal stroke, and hospitalization for heart failure). Results: During the mean follow-up period of 4.6 ± 1.7 years, 441 patients reached the primary endpoints. Kaplan-Meier analysis showed that event-free survival was significantly different between the first and third tertile groups (log-rank test, p < 0.001) in subjects categorized by NGAL levels. In a multivariate Cox proportional hazard regression analysis, plasma NGAL levels were independently associated with an increased risk of MACE [adjusted hazard ratio (aHR) = 1.35; 95% confidence interval (CI) = 1.18–1.54, p < 0.001], AMI (aHR = 1.34; 95% CI = 1.12–1.59, p < 0.001), and target vessel revascularization (aHR = 1.35; 95% CI = 1.19–1.53, p < 0.001). Addition of serum NGAL levels to the traditional risk model improved its prediction value for future cardiovascular events. Conclusions: High plasma NGAL levels were independently associated with the occurrence of MACE and composite cardiovascular events in patients with stable PCI-treat CAD.


  • Open Access

    Potential beneficial impacts of tadalafil on cardiovascular diseases

    by Tien-Yun Lan, Chih-Hung Chiang, Jaw-Wen Chen, Ting-Ting Chang

    Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor commonly used for the treatment of erectile dysfunction and benign prostatic hyperplasia. Its mechanism of action involves the inhibition of PDE5, leading to increased levels of nitric oxide and cyclic guanosine monophosphate in the corpus cavernosum, which facilitates smooth muscle relaxation. This article reviews studies using tadalafil in the treatment of cardiovascular diseases and emphasizes its potential advantages in conditions such as pulmonary arterial hypertension, atherosclerosis, coronary artery disease, myocardial infarction, heart failure, stroke, diabetic ulcers, and cardiomyopathy. Although tadalafil shows potential efficacy in treating cardiovascular disease, further experimental studies are needed to clarify its pharmacological effects on cardiovascular protection beyond PDE5 inhibition.


  • Inhibition of CCL7 improves endothelial dysfunction and vasculopathy in mouse models of diabetes mellitus

    by Ting-Ting Chang, You-Zhen Li, Hsiao-Wei Mo, Ching Chen, Liang-Yu Lin, Chia-Chi Chang, Jaw-Wen Chen

    Diabetic vascular disease is a major complication of diabetes mellitus (DM). Chemokine C-C motif ligand 7 (CCL7) attracts macrophages and monocytes, amplifying inflammatory processes in the vasculature. We hypothesized a causal role for CCL7 in diabetic vasculopathy. CCL7 concentrations were higher in the plasma of patients with type 2 DM, as well as in supernatants from their endothelial progenitor cells (EPCs). High-glucose stimulation increased the secretion of CCL7 from human dermal microvascular endothelial cells (HDMECs) through the c-Fos and c-Jun signaling pathways. CCL7 inhibition using knockdown or neutralization antibody treatment reversed the high glucose–induced impaired tube formation and migration abilities of EPCs, human aortic endothelial cells, human coronary artery endothelial cells, and HDMECs. Administration of recombinant human CCL7 protein impaired tube formation and migration abilities by down-regulating the AKT–endothelial nitric oxide synthase and AKT/nuclear factor erythroid 2–related factor 2/heme oxygenase–1/vascular endothelial growth factor/stromal cell–derived factor–1 pathways and by up-regulating ERK/phosphorylated p65/interleukin-1β/interleukin-6/tumor necrosis factor–α pathways through CC chemokine receptor 3 in endothelial cells. Ccl7 knockout in streptozotocin-treated mice showed improved neovasculogenesis in ischemic limbs and accelerated wound repair, with increased circulating EPCs and capillary density. CCL7 antibody treatment in db/db mice and high-fat diet–induced hyperglycemia mice showed improved neovasculogenesis in ischemic limbs and wound areas, accompanied by up-regulation of angiogenic proteins and down-regulation of inflammatory proteins. Endothelial cell–specific Ccl7 -knockout mice showed ameliorated diabetic vasculopathy in streptozotocin-induced DM. This study highlights the potential of CCL7 as a therapeutic target for diabetic vasculopathy.


  • Open Access

    CCL4 contributes to aging related angiogenic insufficiency through activating oxidative stress and endothelial inflammation

    by Ting-Ting Chang, Liang-Yu Lin, Ching Chen, Jaw-Wen Chen

    Aging is a natural process associated with chronic inflammation in the development of vascular dysfunction. We hypothesized that chemokine C-C motif ligands 4 (CCL4) might play a vital role in aging-related vascular dysfunction. Circulating CCL4 was up-regulated in elderly subjects and in aged animals. CCL4 inhibition reduced generation of reactive oxygen species (ROS), attenuated inflammation, and restored cell functions in endothelial progenitor cells from elderly subjects and in aged human aortic endothelial cells. CCL4 promoted cell aging, with impaired cell functioning, by activating ROS production and inflammation. CCL4 knockout mice and therapeutic administration of anti-CCL4 neutralizing antibodies exhibited vascular and dermal anti-aging effects, with improved wound healing, via the down-regulation of inflammatory proteins and the activation of angiogenic proteins. Altogether, our findings suggested that CCL4 may contribute to aging-related vascular dysfunction via activating oxidative stress and endothelial inflammation. CCL4 may be a potential therapeutic target for vascular protections during aging.


  • Open Access

    Novel prognostic impact and cell specific role of endocan in patients with coronary artery disease

    by Liang-Yu Lin, Ting-Ting Chang, Hsin-Bang Leu, Chin-Chou Huang, Tao-Cheng Wu, Ruey-Hsin Chou, Po-Hsun Huang, Wei-Hsian Yin, Wei-Kung Tseng, Yen-Wen Wu, et al.

    Background: Both the clinical and mechanistic impacts of endocan were not well elucidated especially in coronary artery disease (CAD). Objective: This study aimed to investigate the prognostic and potential pathological role of endocan for cardiovascular (CV) events in stable CAD patients. Methods: A total of 1,071 stable CAD patients with previous percutaneous coronary intervention (PCI) were enrolled prospectively in a nationwide Biosignature study. Another cohort of 76 CAD patients with or without PCI were enrolled for validation. Baseline biomarkers including endocan level was measured and total CV events especially hard CV events (including CV mortality, non-fatal myocardial infection and stroke) during follow-up were identified. Circulating endothelial progenitor cells (EPCs) as an in vivo biological contributor to vascular repairment from CAD patients were used for the in vitro functional study. Results: After 24 months, there were 42 patients (3.92%) with hard CV events and 207 (19.3%) with total CV events in the study group. The incidence of both events was increased with the tertiles of baseline endocan level (hard events: 1.7%,3.4%, and 6.7% in 1st,2nd, and 3rd tertile respectively, p = 0.002; total events: 13.8%vs.16.2%vs.28.0%, p < 0.0001). Multivariate regression analysis revealed the independent association of endocan level with total and hard CV events. These findings were validated in another cohort with a 5-year follow-up. Furthermore, in vitro inhibition of endocan improved cell migration and tube formation capacities, and reduced cell adhesiveness of EPCs from CAD patients. Conclusions: Endocan might be a novel prognostic indicator, mechanistic mediator, and potential therapeutic target for clinical CAD. Graphical